


# Caravaggio

## #ACC20/#WCCardio



AMERICAN  
COLLEGE of  
CARDIOLOGY

**Trial Description:** Cancer patients with proximal deep vein thrombosis or pulmonary embolus were randomized to apixaban vs. dalteparin.



### RESULTS

- Primary efficacy outcome, recurrent proximal deep vein thrombosis/pulmonary embolism: 5.6% of the apixaban group vs. 7.9% of the dalteparin group (p for noninferiority < 0.001)
- Primary safety outcome, bleeding: 3.8% of the apixaban group vs. 4.0% of the dalteparin group (p = 0.60)

### CONCLUSIONS

- Among cancer patients with proximal deep vein thrombosis or pulmonary embolus, apixaban was noninferior compared with subcutaneous dalteparin on prevention of recurrent venous thromboembolism
- There was no increase in major bleeding

Agnelli G, et al. N Engl J Med 2020;Mar 29:[Epub]